INS and type 2 diabetes mellitus: Studies conducted in multiple cell types confirmed that insulin-sensitizing TZDs that had been developed for treatment of type 2 diabetes acted as inhibitors of MPC activity by directly binding to the MPC complex (Divakaruni et al., 2013; McCommis et al., 2015; McCommis and Finck, 2015).